Tang Capital Management LLC Has $23.62 Million Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Tang Capital Management LLC lowered its position in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 2.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,850,000 shares of the biopharmaceutical company's stock after selling 50,000 shares during the quarter. Dynavax Technologies accounts for approximately 1.6% of Tang Capital Management LLC's holdings, making the stock its 16th biggest holding. Tang Capital Management LLC owned about 1.41% of Dynavax Technologies worth $23,624,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. ProShare Advisors LLC grew its stake in shares of Dynavax Technologies by 30.6% in the fourth quarter. ProShare Advisors LLC now owns 45,739 shares of the biopharmaceutical company's stock worth $584,000 after purchasing an additional 10,705 shares in the last quarter. Quantinno Capital Management LP increased its holdings in shares of Dynavax Technologies by 40.2% in the fourth quarter. Quantinno Capital Management LP now owns 18,284 shares of the biopharmaceutical company's stock valued at $233,000 after buying an additional 5,243 shares in the last quarter. Parkman Healthcare Partners LLC lifted its position in shares of Dynavax Technologies by 0.7% during the 4th quarter. Parkman Healthcare Partners LLC now owns 220,980 shares of the biopharmaceutical company's stock valued at $2,822,000 after acquiring an additional 1,529 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Dynavax Technologies by 2.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,796 shares of the biopharmaceutical company's stock worth $1,083,000 after acquiring an additional 2,206 shares in the last quarter. Finally, Jefferies Financial Group Inc. bought a new stake in shares of Dynavax Technologies during the 4th quarter worth $2,462,000. 96.96% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Trading Down 5.0%

Shares of DVAX traded down $0.52 during trading hours on Wednesday, hitting $9.90. 2,519,115 shares of the stock traded hands, compared to its average volume of 2,227,016. The firm has a market capitalization of $1.19 billion, a PE ratio of 55.00 and a beta of 1.26. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a 1-year low of $9.22 and a 1-year high of $14.63. The business has a fifty day moving average of $11.56 and a 200-day moving average of $12.46.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). The business had revenue of $68.16 million during the quarter, compared to analyst estimates of $70.01 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. Analysts expect that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Wall Street Analysts Forecast Growth

DVAX has been the subject of a number of recent analyst reports. JMP Securities decreased their price objective on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. The Goldman Sachs Group lowered their price target on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a report on Thursday, April 17th. StockNews.com downgraded Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday, May 6th. HC Wainwright restated a "buy" rating and set a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Dynavax Technologies has an average rating of "Hold" and an average price target of $24.00.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.